BMS ‘Increasingly Confident’ It Can Handle The Impact Of Medicare Pricing For Eliquis

Pharma To Announce IRA-Mandated Final Price Soon

Bristol’s CEO offered assurances about Medicare negotiations under the IRA as the company delivered better-than-expected second quarter results across new and legacy products.

BMS raised its 2024 revenue guidance based on its Q2 performance • Source: Shutterstock

Now that Bristol Myers Squibb Company has the maximum fair price (MFP) in hand that Medicare intends to pay for Eliquis (apixaban) starting in 2026 under the drug price negotiation authority granted by the Inflation Reduction Act (IRA), CEO Chris Boerner said the company is “increasingly confident in our ability to navigate the impact of IRA on Eliquis.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

11 Apr 2025

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

11 Apr 2025

• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

10 Apr 2025

• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.